Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Recombinant Activated Coagulation Factor VII (rFVIIa) for Treatment of the Tracheobronchial Bleeding in Mechanically Ventilated (MV) Thrombocytopenic Patients (pts)

Gennadii M. Galstian, Olesya A. Polevodova, MD, Vladimir Yu. Zorenko, MD PhD, Valeriy G. Savchenko, MD PhD

Blood (2018) 132 (Supplement 1): 2446.

https://doi.org/10.1182/blood-2018-99-115685

Published: 2018

Journal Articles

The Comparison of Hemostatic Effects of Recombinant Activated Factor VII (rFVIIa) in Thrombocytopenic Patients (pts) and Hemophilia Pts with Inhibitors

Gennadii M. Galstian, MD PhD, Irina V. Kolosova, MD, Eduard Gemdzhian, PhD, Vladimir Yu. Zorenko, MD PhD Prof., Tatyana A. Polyanskaya, MD PhD, Elena B. Orel, MD, Valeri G. Savchenko, MD PhD Prof.

Blood (2015) 126 (23): 4644.

https://doi.org/10.1182/blood.V126.23.4644.4644

Published: 2015

Journal Articles

Safety and Efficiency of New Nonacog Alfa Drug in the Treatment of Bleeding Episodes in Patients with Severe and Moderate Hemophilia B

Igor Davydkin, Prof., Tatiana Andreeva, MD PhD, Vladimir Yu. Zorenko, MD PhD Prof., Valeria Konstantinova, MD PhD, Olga Zalepukhina, MD, Nina Klimova, MD, Georgy Mishin, MD, Igor Kurtov, MD PhD, Maria Shamina, MD PhD, Elena Fatenkova, MD, Olga Gusyakova, MD PhD, Alexandr Shuster, Academician, PhD, Dmitry Kudlay, MD PhD Prof., Sergey Lukyanov, MD PhD, Anton Borozinets, MD PhD, Eugene Nikitin, MD PhD, Ekaterina Klykova, MD PhD

Blood (2015) 126 (23): 4690.

https://doi.org/10.1182/blood.V126.23.4690.4690

Published: 2015

Journal Articles

The Pharmacokinetic Properties, Safety and Tolerability of a New Nonacog Alfa (Innonafactor) in Patients with Hemophilia B

Vladimir Yu. Zorenko, MD PhD Prof., Georgy Mishin, MD, Tatiana Severova, MD, Alexandr Shuster, Academician, PhD, Dmitry Kudlay, MD PhD Prof., Sergey Lukyanov, MD PhD, Anton Borozinets, MD PhD, Eugene Nikitin, MD PhD, Ekaterina Klykova, MD PhD

Blood (2015) 126 (23): 4691.

https://doi.org/10.1182/blood.V126.23.4691.4691

Published: 2015

Journal Articles

Safety and Efficacy of New Nonacog Alfa Drug (Innonafactor) in Prophylactic Treatment in Patients with Severe and Moderate Hemophilia B

Tatiana Andreeva, MD PhD, Vladimir Yu. Zorenko, MD PhD Prof., Igor Davydkin, Prof., Valeria Konstantinova, MD PhD, Olga Zalepukhina, MD, Nina Klimova, MD, Georgy Mishin, MD, Igor Kurtov, MD PhD, Maria Shamina, MD PhD, Elena Fatenkova, MD, Olga Gusyakova, MD PhD, Alexandr Shuster, Academician, PhD, Dmitry Kudlay, MD PhD Prof., Sergey Lukyanov, MD PhD, Anton Borozinets, MD PhD, Eugene Nikitin, MD PhD, Ekaterina Klykova, MD PhD

Blood (2015) 126 (23): 3532.

https://doi.org/10.1182/blood.V126.23.3532.3532

Published: 2015

NARROW

Recombinant Activated Coagulation Factor VII (rFVIIa) for Treatment of the Tracheobronchial Bleeding in Mechanically Ventilated (MV) Thrombocytopenic Patients (pts)

The Comparison of Hemostatic Effects of Recombinant Activated Factor VII (rFVIIa) in Thrombocytopenic Patients (pts) and Hemophilia Pts with Inhibitors

Safety and Efficiency of New Nonacog Alfa Drug in the Treatment of Bleeding Episodes in Patients with Severe and Moderate Hemophilia B

The Pharmacokinetic Properties, Safety and Tolerability of a New Nonacog Alfa (Innonafactor) in Patients with Hemophilia B

Safety and Efficacy of New Nonacog Alfa Drug (Innonafactor) in Prophylactic Treatment in Patients with Severe and Moderate Hemophilia B

Email alerts

ASH Publications

American Society of Hematology

Recombinant Activated Coagulation Factor VII (rFVIIa) for Treatment of the Tracheobronchial Bleeding in Mechanically Ventilated (MV) Thrombocytopenic Patients (pts)

The Comparison of Hemostatic Effects of Recombinant Activated Factor VII (rFVIIa) in Thrombocytopenic Patients (pts) and Hemophilia Pts with Inhibitors

Safety and Efficiency of New Nonacog Alfa Drug in the Treatment of Bleeding Episodes in Patients with Severe and Moderate Hemophilia B

The Pharmacokinetic Properties, Safety and Tolerability of a New Nonacog Alfa (Innonafactor) in Patients with Hemophilia B

Safety and Efficacy of New Nonacog Alfa Drug (Innonafactor) in Prophylactic Treatment in Patients with Severe and Moderate Hemophilia B

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only